Skip to main content
Premium Trial:

Request an Annual Quote

Court Permanently Bars Stratagene from Selling FullVelocity Products; Company Vows to Appeal

NEW YORK, Sept. 30 (GenomeWeb News) - A US district court has permanently barred Stratagene from selling its FullVelocity QPCR and QRT-PCR products, which the court said  infringe two patents held by Third Wave Technologies, Third Wave said yesterday.

 

The injunction, issued by the US District Court for the Western District of Wisconsin, prohibits Stratagene from manufacturing, selling, and offering these or any other products that violate Third Wave's US patents Nos. 6,090,543 and 6,348,314. Stratagene must also notify its customers and collaborators about the infringement.

 

Earlier this month, a jury found that Stratagene willfully infringed Third Wave's patents and awarded Third Wave $5.29 million in damages. Third Wave, which  filed the suit last September, said it is seeking additional damages and expects a decision by the court by the end of the year.

 

Stratagene said today in a response that it intends to file an appeal in the Court of Appeals for the Federal Circuit in Washington, DC, "as soon as practicable." The company will seek to have the injunction lifted and the damages reduced or eliminated.

 

On May 6, Stratagene  countersued Third Wave in the US District Court for the District of Delaware, which is still pending, claiming that Third Wave infringes its Full Velocity technology. Stratagene seeks monetary damages and a permanent injunction to prevent Third Wave from selling its Invader Plus products.

 

Stratagene reiterated today that its infringing Full Velocity products have contributed less than $400,000 in revenues since they were made available last year, and that other embodiments of the FullVelocity technology do not infringe Third Wave's patents.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.